Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells by Matsuzaki, Koichi
REVIEW
Smad phosphoisoform signals in acute and chronic liver
injury: similarities and differences between epithelial
and mesenchymal cells
Koichi Matsuzaki
Received: 7 March 2011 /Accepted: 15 April 2011 /Published online: 31 May 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Hepatocellular carcinoma (HCC) usually arises
from hepatic fibrosis caused by chronic inflammation. In
chronic liver damage, hepatic stellate cells undergo
progressive activation to myofibroblasts (MFB), which are
important extracellular-matrix-producing mesenchymal
cells. Concomitantly, perturbation of transforming growth
factor (TGF)-β signaling by pro-inflammatory cytokines in
the epithelial cells of the liver (hepatocytes) promotes both
fibrogenesis and carcinogenesis (fibro-carcinogenesis).
Insights into fibro-carcinogenic effects on chronically
damaged hepatocytes have come from recent detailed
analyses of the TGF-β signaling process. Smad proteins,
which convey signals from TGF-β receptors to the nucleus,
have intermediate linker regions between conserved Mad
homology (MH) 1 and MH2 domains. TGF-β type I
receptor and pro-inflammatory cytokine-activated kinases
differentially phosphorylate Smad2 and Smad3 to create
phosphoisoforms phosphorylated at the COOH-terminal,
linker, or both (L/C) regions. After acute liver injury, TGF-
β-mediated pSmad3C signaling terminates hepatocytic
proliferation induced by the pro-inflammatory cytokine-
mediated mitogenic pSmad3L pathway; TGF-β and pro-
inflammatory cytokines synergistically enhance collagen
synthesis by activated hepatic stellate cells via pSmad2L/C
and pSmad3L/C pathways. During chronic liver disease
progression, pre-neoplastic hepatocytes persistently affected
by TGF-β together with pro-inflammatory cytokines come
to exhibit the same carcinogenic (mitogenic) pSmad3L and
fibrogenic pSmad2L/C signaling as do MFB, thereby
accelerating liver fibrosis while increasing risk of HCC.
This review of Smad phosphoisoform-mediated signals
examines similarities and differences between epithelial
and mesenchymal cells in acute and chronic liver injuries
and considers Smad linker phosphorylation as a potential
target for the chemoprevention of fibro-carcinogenesis.
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Introduction
The incidence of hepatocellular carcinoma (HCC) is rising
in North America, Europe, and Eastern countries such as
China (El-Serag and Rudolph 2007). This increase is
largely attributable to the emergence of hepatitis C virus
(HCV) and to continued difficulties with the control of
hepatitis B virus (HBV) infection (Koike 2002; Llovet et al.
2003). The inflammatory response triggered by hepatitis
viral infection is part of the normal host defense, whose
goal is pathogen elimination. However, carcinogenic
pathogens subvert host immunity and establish persistent
infections associated with low-grade chronic inflammation.
If hepatitis viruses are not cleared in the acute phase of
infection, the patients can develop chronic hepatitis. Some
patients subsequently develop liver fibrosis as a result of
chronic liver damage, characterized by extracellular matrix
(ECM) accumulation that distorts hepatic architecture by
forming a fibrous scar (Friedman 2010). Ultimately,
nodules of regenerating hepatocytes become enclosed by
scar tissue, an event defining cirrhosis. As human livers
infected by hepatitis viruses progress from chronic hepatitis
to cirrhosis, HCC occurrence increases (Tsukuma et al.
1993). Most HCC cases have a natural history of
unresolved inflammation and severe fibrosis (or cirrhosis)
irrespective of the underlying cause of liver disease (Omata
and Yoshida 2004). Approaches to understanding the way
that human HCC develops in chronic liver diseases should
therefore focus on molecular mechanisms shared in common
between fibrosis and carcinogenesis (fibro-carcinogenesis)
caused by chronic inflammation.
After acute liver injury, mesenchymal cells including
hepatic stellate cells (HSC) activated by transforming
growth factor (TGF)-β and pro-inflammatory cytokines
promote tissue remodeling by deposition of a collagen-rich
ECM (Friedman 2010). The seemingly key roles of TGF-β
in liver fibrosis argue for the application of TGF-β
inhibitors in the treatment of chronic liver diseases.
However, in order to maintain liver homeostasis after acute
liver injury, TGF-β activity is needed to terminate the
proliferation of hepatocytes, the epithelial cells of the liver,
induced by pro-inflammatory cytokine-mediated mitogenic
signaling. In this respect, TGF-β has received serious
consideration as a candidate tumor-suppressive cytokine
during chronic liver diseases (Derynck and Miyazono 2008).
Before clinical attempts of the blockage of fibrogenic TGF-β
signaling in human chronic liver disorders, we need to study
the way that TGF-β signaling is perturbed by pro-
inflammatory cytokines during human chronic liver diseases
in which hepatocytes, together with HSC, induce fibro-
carcinogenesis. Consideration should also be given to the
physiologic roles of TGF-β and pro-inflammatory cytokine
signals, which differ between regenerative hepatocytes and
collagen-producing HSC after acute liver injury.
The TGF-β superfamily is composed of many multi-
functional cytokines, including TGF-β, activin, and bone
morphogenic protein (Roberts and Sporn 1990; Derynck
and Miyazono 2008). Progress over the past 10 years has
disclosed important details of the manner in which the
TGF-β family elicits its responses (Heldin et al. 1997;
Wrana 2000; Shi and Massagué 2003; Guo and Wang
2009). Smads, central mediators conveying signals from
receptors for TGF-β superfamily members to the nucleus,
are modular proteins with conserved Mad-homology (MH)
1, intermediate linker, and MH2 domains (Shi and
Massagué 2003). In cell-signaling pathways, various
transcription factors are phosphorylated at multiple sites
by upstream kinases. Catalytically active TGF-β type I
receptor (TβRI) and activin type I receptor (ActRI)
phosphorylate COOH-tail serine residues of receptor-
activated Smad (R-Smad), which include Smad2 and the
highlysimilarproteinSmad3(Wrana2000). Mitogenic signals
alternatively cause the phosphorylation of R-Smad at specific
sites in its middle linker regions (Kretzschmar et al. 1999;
Mori et al. 2004;M a t s u u r ae ta l .2004; Kamaraju and Roberts
2005;S e k i m o t oe ta l .2007; Matsuzaki et al. 2009). Once
phosphorylated R-Smad has rapidly oligomerized with
Smad4, this complex translocates to the nucleus, where it
regulates the transcription of target genes.
Monitoring of the phosphorylation status of signaling
molecules is a key step in dissecting their pathways. In Smad
signaling, the phosphorylation of not only the COOH-tail, but
also the linker regions of R-Smad is likely to be important in
regulating Smad activity under physiologic and pathologic
conditions (Liu 2006). In this review, we first examine Smad
signaling specificity derived from the spatial and temporal
dynamics of domain-specific R-Smad phosphorylation in
response to TGF-β and/or pro-inflammatory cytokines. We
next consider the way in which these phosphorylated R-Smad
signals determine specific cellular responses to TGF-β/pro-
inflammatory cytokines in hepatocytes and HSC after acute
liver injury. Then, we examine the phosphorylated R-Smad
signals shared by both hepatocytes and HSC in chronic liver
injury, by which these cells continuously transmit a fibro-
carcinogenic signal. Finally, we consider how the enhanced
understanding of phosphorylated R-Smad signaling could
lead to improved methods for the prevention of human
fibro-carcinogenesis.
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A complex interplay among the various hepatic cell types
takes place in injured livers (Fig. 1). Hepatocytes are targets
for most hepatotoxic agents, including hepatitis viruses,
alcohol metabolites, and chemical toxins (Taub 2004).
Damaged hepatocytes induce the recruitment of white
blood cells by local inflammatory cells. Apoptosis of
damaged hepatocytes stimulates fibrogenesis by Kupffer
cells, the resident macrophages of the liver. Activated
Kupffer cells secrete pro-inflammatory cytokines including
tumor necrosis factor (TNF)-α and interleukins (IL), plus
TGF-β. Intensive studies have shown that HSC are the
major cell type responsible for matrix production in
damaged liver tissues (Pinzani and Macias-Barragan
2010). HSC, characterized by retinoid droplets in the
cytoplasm, are present in the space of Disse (Friedman
2010). After liver injury, activated HSC secrete large
amounts of ECM proteins.
Hepatic fibrosis results from a wound-healing response
to repeated liver injury (Bataller and Brenner 2005). HSC
undergo a dramatic phenotypic activation in chronic liver
diseases, with the acquisition of fibrogenic properties.
Hepatic mesenchymal cell types other than activated HSC
also have fibrogenic potential: portal fibroblasts of bone
marrow origin have been identified as collagen-producing
cells in injured livers (Ramadori and Saile 2004). The
distribution of fibrous material depends upon the etiology
of liver injury. In chronic viral hepatitis and chronic
cholestatic disorders, fibrosis originates in periportal regions,
whereas in alcohol-induced liver disease and after CCl4
intoxication, fibrosis is pericentral. Hepatocytes are replaced
with abundant ECM, mainly in the form of fibrillar collagen.
Sinusoidal endothelial cells lose their fenestrations, and tonic
contraction of HSC increases resistance to blood flow in the
hepatic sinusoids.
A new concept has been proposed that epithelial cells
undergoaphenotypicalchangecalledepithelial-mesenchymal
transition(EMT)toacquireafibroblasticphenotype.EMTisa
mechanism that facilitates metastasis and cancer development
(Weinberg 2007). Pioneering studies of EMT in the field of
organ fibrosis have been accomplished in the kidney, lens,
and lung (Iwano et al. 2002; Saika et al. 2004). EMT has
also been postulated to promote liver fibrosis. Zeisberg et al.
(2007) have demonstrated that hepatocytes acquire the
expression of fibroblast specific protein 1 in response to
Fig. 1 Changes in hepatic architecture (a) associated with advanced
hepatic fibrosis (b). Following liver injury, lymphocytes infiltrate the
hepatic parenchyma. Some hepatocytes undergo apoptosis, and Kupffer
cells are activated to release fibrogenic mediators such as transforming
growth factor-β (TGF-β) and tumor necrosis factor-α (TNF-α). In
response to these cytokines, hepatic stellate cells (HSC) transdifferentiate
into myofibroblast-like cells and come to secrete large amounts
of extracellular material (ECM) proteins. Affected hepatocytes also
participate in liver fibrogenesis by stimulating the deposition of ECM
proteins. As liver fibrosis progresses, sinusoidal endothelial cells lose
their fenestrations, with tonic contraction of HSC increasing resistance to
blood flow in hepatic sinusoids
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have been suggested to undergo EMT (Omenetti et al. 2008).
However, recent studies indicate that hepatocytes and
cholangiocytes do not contribute directly to the fibrogenic
myofibroblast population in liver fibrosis via EMT (Taura et
al. 2010;S c h o l t e ne ta l .2010). Thus, the controversy over the
concept of EMT in fibrotic diseases, conceived in genetic
mouse models, is far from being resolved (Popov and
Schuppan 2010).
Multiple Smad phosphoisoforms exist
The canonical TGF-β/activin pathway involves Smad2 and
Smad3 signaling through direct serine phosphorylation of
COOH-termini by TβRI/ActRI upon the TGF-β/activin
binding (Shi and Massagué 2003; Derynck and Miyazono
2008;F i g .2a). TβRI/ActRI-mediated phosphorylation of
Smad2 and Smad3 induces their association with the shared
partner Smad4, followed by translocation into the nucleus
where these complexes activate transcription of specific genes
(Heldin et al. 1997;W r a n a2000; Shi and Massagué 2003;
Derynck and Miyazono 2008; Guo and Wang 2009). Smad
proteins contain a conserved Mad-homology (MH)1 domain
that binds DNA, and a conserved MH2 domain that binds
receptors, partner Smad4, and transcription coactivators.
More divergent linker regions separate the two domains
(Shi and Massagué 2003). The linker domain undergoes
regulatory phosphorylation by mitogen-activated protein
kinase (MAPK) pathways including extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK),
p38 MAPK, and cyclin-dependent kinase (CDK)-2/4, and
glycogen synthase kinase 3-β, Ca (2+)-calmodulin-dependent
protein kinase II, and G-protein-coupled receptor kinase-2
(Kretzschmar et al. 1999; Wicks et al. 2000; Furukawa et al.
2003;M o r ie ta l .2004;M a t s u u r ae ta l .2004;K a m a r a j ua n d
Roberts 2005;H oe ta l .2005; Millet et al. 2009; Matsuzaki et
al. 2009; Alarcón et al. 2009;F i g .2b). TGF-β also elicits
signaling responses through non-Smad pathways that are
generally considered as important effecter pathways for TGF-
β activated kinase (TAK) 1 in response to pro-inflammatory
cytokines (Fig. 2a). TAK1 activates JNK and p38 MAPK
signaling through mitogen-activated kinase kinase (MKK) 4/
7 and MKK3/6 (Akira and Takeda 2004;S h i me ta l .2005).
JNK and p38 MAPK have been linked to the modification of
TGF-β signaling by pro-inflammatory cytokines through
their regulation of distinct processes, such as cytoskeleton
organization, cell growth, survival, migration, or invasion (Xu
et al. 2009). Imbalance might occur between signaling
through non-Smad and Smad pathways during fibro-
carcinogenesis, and interaction between these pathways
mediates pro-fibrogenic and pro-tumorigenic effects of
TGF-β (Derynck and Akhurst 2007).
The use of mice with a targeted deletion of Smad3 and
JNK1 as a down-stream mediator of TAK1 indicates that both
Smad3 and JNK1 pathways involve hepatic fibro-
carcinogesis. When acute liver injury is induced by the
administration of CCl4, Smad3
−/− mice show approximately
one-half of the induction of collagen type I mRNA as do
wild-type mice (Schnabl et al. 2001). In JNK1
−/− mice, not
only liver fibrosis, but also HCC development is prevented.
A remarkable collagen deposition in wild-type and JNK2
−/−
mice, but less deposition in JNK1
−/− mice, suggests an
important role for JNK1 in the development of liver fibrosis
(Kodama et al. 2009). JNK1
−/− mice exhibit impaired liver
carcinogenesis with reduced tumor masses, sizes, and
numbers (Hui et al. 2008). Importantly, JNK1
−/− mice
display decreased HCC proliferation in a carcinogenic model
and decreased hepatocytic growth in a model of liver
regeneration. In both cases, the impaired proliferation is
caused by the increased expression of p21
WAF1, a cell-cycle
inhibitor, and the reduced expression of c-Myc, a negative
regulator of p21
WAF1.
Pro-inflammatory cytokines simultaneously activate linker-
phosphorylated R-Smad and non-Smad signaling, with both
usually operating in parallel. The biological significance of
linker-phosphorylated R-Smad pathways is therefore difficult
to assess in isolation. Here, we will review recent work in this
area, with a particular focus on the way that the pro-
inflammatory cytokines modulate TGF-β signaling through
R-Smad linker phosphorylation, by using hepatic fibro-
carcinogenesis as an example. Antibodies (Abs) reactive with
structurally related phosphorylated peptides are emerging as
valuable tools for determining phosphorylation sites in vivo
and for investigating their distinct signals via phosphorylated
domains. Domain-specific phospho-R-Smad Abs have allowed
us to reveal that TβRI/ActRI and JNK/CDK4 differentially
phosphorylate R-Smad to create three phosphorylated forms
(phosphoisoforms): COOH-terminally phosphorylated
R-Smad (pSmad2C and pSmad3C), linker phosphorylated
R-Smad (pSmad2L and pSmad3L), and dually phosphorylated
R-Smad(pSmad2L/CandpSmad3L/C;Matsuzaki2006, 2009;
Sapkota et al. 2006;W r i g h t o ne ta l .2009). Except for
pSmad2L with its cytoplasmic localization (Kretzschmar et al.
1999; Yamagata et al. 2005), the other phosphoisoforms are
localized to the cell nuclei (Furukawa et al. 2003;M o r ie ta l .
2004; Yamagata et al. 2005; Yoshida et al. 2005;S e k i m o t oe t
al. 2007; Matsuzaki et al. 2007, 2009;M u r a t ae ta l .2009;
Nagata et al. 2009; Alarcón et al. 2009; Kawamata et al. 2011;
Fig. 2c). Linker phosphorylation can modify COOH-
terminally phosphorylated R-Smad signaling (Kretzschmar et
al. 1999;M o r ie ta l .2004;M a t s u u r ae ta l .2004;H oe ta l .
2005;S e k i m o t oe ta l .2007; Matsuzaki et al. 2009).
Differential localization of kinases and phosphatases in the
cytoplasm or nucleus raises the intriguing possibility of
different temporal dynamics for cytoplasmic or nuclear
228 Cell Tissue Res (2012) 347:225–243Fig. 2 Three Smad
phosphoisoform types:
pSmad2C and pSmad3C,
pSmad2L and pSmad3L, and
pSmad2L/C and pSmad3L/C.
a The canonical TGF-β
signaling pathways. Following
phosphorylation (P) on their
carboxyl termini by TGF-β
type I receptor (TβRI), Smad2
and Smad3 partner with the
common mediator Smad4
translocate to the nucleus. Not
only TNF-α, but also TGF-β
activates c-Jun N-terminal
kinase (JNK) and p38
mitogen-activated protein
kinase (MAPK) through
mitogen-activated kinase
kinase 4/7 (MKK4/7) and
MKK3/6 activated by TGF-β
activated kinase 1 (TAK1).
JNK and p38 MAPK
phosphorylate other
transcription factors, such
as c-Jun and activating
transcription factor 2 (ATF-2),
that cooperate with nuclear
Smads in mediating TGF-β-
induced transcriptional
responses (SBE Smad-binding
element, TBE transcription
factor binding element).
b Representation of
phosphorylation sites in
Smad2 and Smad3.
Catalytically active TβRI
and Activin type I receptor
(ActRI) phosphorylate
COOH-tail serine residues.
JNK and cyclin-dependent
kinase (CDK) alternatively
phosphorylate Smad2/3 at
specific sites in their middle
linker regions. c TβRI/ActRI
and JNK/CDK differentially
phosphorylate Smad2/3 to
create three phosphorylated
forms (phosphoisoforms):
COOH-terminally
phosphorylated Smad2/3
(pSmad2C and pSmad3C),
linker phosphorylated Smad2/3
(pSmad2L and pSmad3L), and
dually phosphorylated Smad2/3
(pSmad2L/C and pSmad3L/C).
Cytoplasmic localization is
seen for pSmad2L, whereas
the other phosphoisoforms
localize to the cell nuclei
Cell Tissue Res (2012) 347:225–243 229R-Smad phosphoisoforms and adds to the repertoire of
signaling responses that determine cell-fate decisions (another
related review, manuscript in preparation). Immunohistochem-
ical and immunofluorescence analyses with specific Abs in
human tissues can be used to examine the clinical significance
of context-dependent and cell-type-specific signaling mediated
by R-Smad phosphoisoforms, by the comparison of the tissue/
cellular localization of these phosphoisoforms in various
pathologic specimens.
Cytostatic TGF-β/activin signaling: involvement
of the pSmad3C pathway
Both TGF-β and activin inhibit the proliferation of normal
hepatocytes, thus being crucial for hepatic homeostasis
(Fausto et al. 2006). In the context of cell cycle control, the
most important targets of action by TGF-β/activin are the
genes encoding two CDK inhibitors (p21
WAF1 and
p15
INK4B) and c-Myc (Massagué 2008). The pSmad3C
signal induces the expression of these CDK inhibitors and
represses the expression of c-Myc, shutting down cell cycle
progression in the early/mid-G1 phase of the cell cycle
(Fig. 3a). Development of HCC is ordinarily blocked
through the actions of the pSmad3C pathway, which can
cause normal hepatocytes to cease growth and enter
apoptosis after hepatocytic proliferation, in part through
the ability of pSmad3C to induce or repress the expression
of various apoptosis-associated proteins such as Bcl2 (Yang
et al. 2006).
Mitogenic JNK signaling: involvement of the pSmad3L
pathway
Pro-inflammatory cytokines strongly activate the JNK
pathway, whereas TGF-β/activin activates it more weakly
 Fig. 3 Reversible shifting of Smad3-dependent signaling between
hepatocytic growth and inhibition indicates that pSmad3C transmits a
cytostatic TGF-β/activin signal, whereas pro-inflammatory cytokines
transmit a mitogenic signal through the JNK-dependent pSmad3L
pathway. a TGF-β or activin treatment activates TβRI or ActRI, further
leading to the direct phosphorylation of Smad3C. pSmad3C inhibits
hepatocyte growth by up-regulating p21
WAF1 transcription. b Although
TGF-β and the activin signal weakly phosphorylate Smad3L in normal
hepatocytes (dotted arrow), pro-inflammatory cytokines can transmit a
mitogenic signal through the JNK-dependent pSmad3L pathway to
participate in hepatocytic growth, possibly by stimulating the transcription
of the c-Myc gene. Linker phosphorylation of Smad3 indirectly prevents
its COOH-tail phosphorylation (yellow star), pSmad3C-mediated
p21
WAF1 transcription, and consequently the cytostatic effect of TGF-β/
activin upon normal hepatocytes. c Either various JNK inhibitors or a
Smad3 mutant lacking the JNK phosphorylation sites in the linker region
can eliminate mitogenic pSmad3L signaling and restore the lost cytostatic
pSmad3C signaling observed in mature hepatocytes
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has previously been shown to induce the phosphorylation of
Smad2 and Smad3 at their linker regions (Kretzschmar et al.
1999). Smad2 phosphorylation at the linker region inhibits
the nuclear accumulation of Smad2 without interfering with
the TGF-β-induced phosphorylation of its COOH-tail (de
Caestecker et al. 1998; Lehmann et al. 2000; Yue and
Mulder 2000; Oft et al. 2002; Funaba et al. 2002; Janda et al.
2002; Suzuki et al. 2007; Matsuzaki et al. 2009;L ie ta l .
2009; Burch et al. 2010; Jiang et al. 2010). In contrast, linker
phosphorylation does not retain Smad3 in the cytoplasm,
permitting further consequences of the Ras/MAPK signaling.
The mechanisms underlying this difference between the two
R-Smads are not known, but the phosphorylation sites of
Smad3 at clusters of three serine residues in its linker region
(Ser
204,S e r
208, and Ser
213) are different in sequence from the
corresponding linker phosphorylation sites (Ser
245,S e r
250,
and Ser
255) of Smad2 (Fig. 1b).
Several lines of evidence indicate that JNK transmits a
mitogenic signal via the pSmad3L pathway (Fig. 3b). First,
pro-inflammatory cytokines induce Smad3 phosphorylation
at its linker region (Matsuzaki et al. 2007; Kawamata et al.
2011). Second, JNK can directly phosphorylate the linker
site in vitro, and JNK inhibitors block linker phosphorylation
in vivo (Mori et al. 2004; Sekimoto et al. 2007). Third,
mitogens translocate pSmad3L into the nucleus (Mori et al.
2004;S e k i m o t oe ta l .2007; Matsuzaki et al. 2009). Fourth,
nuclear pSmad3L forms a hetero-complex with Smad4
(Furukawa et al. 2003;M o r ie ta l .2004). Fifth, nuclear
pSmad3L binds to the Smad-binding element in the
promoter with high affinity and specificity (Furukawa et al.
2003;W a n ge ta l .2005; Prokova et al. 2005; Vasilaki et al.
2009). Finally, mitogens induce the growth of normal
epithelial cells by up-regulating c-Myc, and such mitogenic
effects are blocked by Smad3 mutants lacking linker
phosphorylation sites and by JNK inhibitors (Sekimoto et
al. 2007). These results strongly support the notion that JNK
specifically signals through Smad3 (Engel et al. 1999).
Reversibility of phospho-Smad3 signaling between
epithelial cell growth and inhibition
JNK-mediated pSmad3L and TβRI/ActRI-mediated pSmad3C
signals oppose each other; most importantly, the balance
between cell growth and inhibition can shift (Fig. 3). Linker
phosphorylation of Smad3 blocks COOH-tail phosphorylation
induced by TβRI/actRI (Mori et al. 2004;H oe ta l .2005;
Sekimoto et al. 2007;M u r a t ae ta l .2009; Nagata et al. 2009;
Fig. 3b, star). Mitogenic signaling accelerates the nuclear
transport of pSmad3L from the cytoplasm, while preventing
Smad3C phosphorylation, pSmad3C-mediated transcription,
and the anti-proliferative effects of TGF-β/activin (Sekimoto
et al. 2007). Smad3 mutants lacking linker phosphorylation
sites, and JNK inhibitors, can restore growth inhibitory
and transcriptional responses to TGF-β/activin in Ras-
transformed cells and pre-neoplastic hepatocytes, both in
vitro and in vivo (Sekimoto et al. 2007;M u r a t ae ta l .2009;
Nagata et al. 2009;F i g .3c). Our model implies that the JNK
pathway directly or indirectly modulates pSmad3C- and
pSmad3L-mediated signaling to regulate target genes,
resulting in an antagonistic relationship between cell growth
and inhibition. Thus, the effectiveness of cytostatic TGF-β/
activin signaling can depend on the extent of Smad3
phosphorylation at the linker region.
Mesenchymal TGF-β signaling: involvement
of the pSmad2L/C and pSmad3L/C pathways
Recent clarification of the molecular aspects of Smad
phosphoisoform signaling further offers potential for
understanding the molecular mechanisms regulating growth
inhibitionversus stimulation by TGF-βinfibroblasts.OnlyRb
family members were originally known to be substrates of
CDK4, until the Liu group reported that Smad3 is phosphor-
ylated by both CDK4 and CDK2 in vivo and in vitro
(Matsuura et al. 2004). CDK4-mediated phosphorylation of
Smad3 at its linker region inhibits its transcriptional activity
and the anti-proliferative activity of TGF-β in fibroblasts
(Matsuura et al. 2004;W a n ge ta l .2009). Importantly,
COOH-tail phosphorylation of Smad3 is necessary for
TGF-β-induced phosphorylation of Smad3 at its linker region
in fibroblasts (Wang et al. 2009;M a t s u u r ae ta l .2010).
Consistent with these observations concerning Smad3, we
have confirmed that the nuclear cyclin D1·CDK4 complex of
fibroblasts activated by TGF-β, pro-inflammatory cytokines,
and platelet-derived growth factor (PDGF) signaling directly
phosphorylates the linker segment of pSmad2C to produce
pSmad2L/C (Matsuzaki et al. 2009; unpublished data).
Other nuclear CDK members including CDK8 and CDK9
phosphorylate the linker portions of pSmad1C, pSmad2C,
and pSmad3C to create pR-SmadL/C (Alarcón et al. 2009).
The expression of c-Myc in fibroblasts is initially repressed
by TGF-β, but subsequent cyclin D1·CDK4 undergoes a
complete functional change to stimulate c-Myc (Matsuzaki et
al. 2009). In contrast, TGF-β persistently inhibits c-Myc
expression and growth in fibroblasts carrying Smad2/3
mutants lacking CDK4 phosphorylation sites in their linker
regions (Fig. 2b). Collectively, TGF-β inhibits cell growth by
down-regulating the c-Myc oncoprotein via the pSmad2C
and pSmad3C pathways (Fig. 4a, left). However, signaling
activated by TGF-β, pro-inflammatory cytokines, and PDGF
can enhance fibroblast growth by up-regulating c-Myc via the
CDK4-dependent pSmad2L/C and pSmad3L/C pathways in
cell nuclei (Fig. 4a, right).
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factors, chemokines, and oxidative stress products, play a
role in the activation of HSC (Friedman 2010). Among
cytokines, TGF-β is the most potent stimulus for the
production of collagen by activated HSC (Inagaki and
Okazaki 2007; Kisseleva and Brenner 2008). Pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-6
are not only mitogenic, but also pro-fibrotic (Kisseleva and
Brenner 2008; Grivennikov et al. 2010). PDGF acts as a
potentmitogenforHSCviatheRaspathwayandisinvolvedin
tissue repair after liver damage (Pinzani and Macias-Barragan
2010). Collagen synthesis by mesenchymal cells including
fibroblasts, mesangial cells, and HSC appears to be promoted
by pSmad2L/C and pSmad3L/C. Li et al. (2009)h a v e
reported that ERK2 enhances the TGF-β1-induced synthesis
of type I and III collagen in fibroblasts, accompanied by
Smad2 phosphorylation at linker sites. Ablation of ERK2
significantly down-regulates the synthesis of collagen I and
III. In support of this finding, Jiang et al. (2010) have recently
reported that pSmad2L/C induced by both TβRI and Erk/
Fig. 4 Spatial and temporal
dynamics of R-Smad
phosphoisoforms differing
between HSC and MFB.
a Phospho-Smad signaling
in HSC: involvement of
pSmad2L/C and pSmad3L/C
pathways. TGF-β inhibits HSC
growth by down-regulating
c-Myc oncoprotein via the
pSmad2C and pSmad3C
pathways (left); TGF-β,
TNF-α, and PDGF, in turn,
enhance HSC growth and
collagen synthesis by
up-regulating the transcription
of c-Myc and collagen via the
pSmad2L/C and pSmad3L/C
pathways (right).
b Phospho-Smad signaling
in MFB: involvement of the
mitogenic pSmad3L and
the fibrogenic pSmad2L/C
pathways. TNF-α activates
JNK, which phosphorylates
Smad2L and Smad3L (left).
After the COOH-tail
phosphorylation of
cytoplasmic pSmad2L by
TβRI, pSmad2L/C undergoes
translocation to the nucleus,
where it interacts with
pSmad3L and Smad4. The
Smad complex then stimulates
plasminogen activator
inhibitor-1 (PAI-1)
transcription and ECM
deposition (right)
232 Cell Tissue Res (2012) 347:225–243JNK enhances the synthesis of collagen IV in rat mesangial
cells. On the other hand, Hayashida et al. (2003)h a v ef o u n d
that the ERK-dependent phosphorylation of Smad3L
increases collagen I synthesis by human mesangial cells
in response to TGF-β. Moreover, we have shown that the
co-treatment of primary cultured HSC with TGF-β and
PDGF enhances the transcription of the collagen I gene
via the pSmad3L/C pathway (Furukawa et al. 2003; Yoshida
et al. 2005).
Fibrogenic pSmad2L/C together with mitogenic
pSmad3L pathways characterize TGF-β signaling
in myofibroblasts
Hepatic fibrosis is characterized by the accumulation of
excess ECM proteins, regardless of the underlying etiology.
The amount of matrix deposition reflects a balance between
its synthesis and degradation (Arthur 2000; Popov and
Schuppan 2009). When the synthesis of ECM exceeds its
degradation, the pathologic accumulation of ECM leads to
liver fibrosis. The reversibility of experimental hepatic
fibrosis and the striking decrease in collagenolytic activity
observed in liver fibrosis models suggest the crucial
importance of impaired matrix degradation in hepatic
fibrogenesis (Pinzani and Macias-Barragan 2010). The
plasminogen activator/plasmin system, which is situated
upstream of the fibrolysis system, can directly degrade
matrix component and indirectly inhibit ECM deposition
(Eddy 2009). Plasminogen activator inhibitor-1 (PAI-1), the
major physiologic inhibitor of plasminogen activator, is a
potent promoter of fibrosis (Ha et al. 2009). PAI-1 also has
a role in migration and invasion for various mesenchymal
cells (Kwaan and McMahon 2009).
Methods of obtaining HSC from livers are now standardized
(Kawada 1997), and the prolonged culture of HSC on
plastic is widely accepted as a model of liver fibrosis
(Friedman 2010). HSC spontaneously transdifferentiate to a
myofibroblast (MFB) phenotype on plastic dishes, and this
response recapitulates the features of activation in vivo. MFB
usually retain the fibrogenic TGF-β signaling component but
have lost the capacity to respond to TGF-β with growth arrest
(Inagaki and Okazaki 2007). Such a state of altered TGF-β
responsiveness is also observed in Ras-transformed cells,
which typically exhibit a limited growth inhibitory response to
TGF-β, instead responding to TGF-β with invasive and
metastatic behavior (Oft et al. 1996, 2002).
A clue to the molecular mechanisms underlying this
change is suggested by the differential cellular localization
of pSmad2L and pSmad3L observed in both MFB and Ras-
transformed cells (Fig. 2c). JNK activated by either pro-
inflammatory cytokines or hyperactive Ras stimulates the
retention of most Smad2 protein in the cytoplasm
(Kretzschmar et al. 1999;S e k i m o t oe ta l .2007)b u t
facilitates the nuclear accumulation of pSmad3L (Furukawa
et al. 2003; Sekimoto et al. 2007; Matsuzaki et al. 2007,
2009; Kawamata et al. 2011), while inhibiting tumor-
suppressive pSmad3C signaling (Fig. 3b, left). Smad2 can
accumulate in the nucleus only if its C-terminus is
phosphorylated under conditions of sustained linker phos-
phorylation by JNK. After COOH-tail phosphorylation of
cytoplasmic pSmad2L by TβRI, pSmad2L/C undergoes
translocation to the nucleus where it binds to the pSmad3L
and Smad4 complex (Furukawa et al. 2003; Matsuzaki et
al. 2009; Fig. 4b, right), which then in turn stimulates PAI-1
transcription (Furukawa et al. 2003). Promotion of PAI-1
expression and cellular invasion requires both complete
linker and COOH-tail phosphorylation of Smad2, indicating
that TGF-β induces the deposition of ECM and invasion via
the pSmad2L/C pathway (Furukawa et al. 2003;M a t s u z a k i
et al. 2009). As a result, MFB lose growth-inhibitory
responsiveness to TGF-β, while TGF-β can accelerate
ECM accumulation and invasion.
Phospho-Smad signaling in hepatocytes after acute liver
injury: mitogenic pSmad3L signaling followed
by cytostatic pSmad3C signaling
A unique feature of adult mammalian liver is its ability to
regenerate accurately lost mass, which occurs following
surgical resection or diffuse liver injury (Michalopoulos
2007). Although the precise identity of the cytokines and
the molecular mechanisms involved in liver regeneration
are largely unknown, activin A appears to be a likely
negative regulator of hepatocytic growth in static situations
(Yasuda et al. 1993). Both activin A and its receptors are
expressed in quiescent hepatocytes, and activin A inhibits
the initiation of mitogen-induced DNA synthesis in
hepatocytes (Date et al. 2000a). Blocking of the action of
activin A by the addition of the activin antagonist follistatin
or transfection with the follistatin gene or a dominant-
negative activin receptor gene initiates DNA synthesis in
normal liver and thereby increases liver volume (Kogure et
al. 1995). In addition, quiescent hepatocytes show evidence
of persistent phosphorylation of Smad3 at its C-terminus
(Matsuzaki et al. 2007; Murata et al. 2009; Nagata et al.
2009; Fig. 5a, upper left).
Hepatocytes initiate the transition from the resting to the
proliferative state after acute liver injury and partial
hepatectomy (Michalopoulos 2007). Loss of parenchyma
rapidly induces a wave of hepatocytic proliferation to
restore the total mass of the liver to normal. Several
converging lines of evidence have established that pro-
inflammatory cytokines such as TNF-α a n dI L - 6a r e
important components of the mitogenic pathways leading
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2010). Treatment of hepatocytes with antibodies against
TNF-α results in decreased DNA synthesis and JNK
activity (Fausto et al. 2006). DNA synthesis during liver
regeneration is severely impaired in mice with TNF-α type
I receptor deficiency (Yamada et al. 1997). After acute liver
injury, however, both TGF-β and activin A increase in the
damaged livers within a time frame similar to that of pro-
Fig. 5 Smad phosphoisoform-
mediated signals showing
similarities and differences
between hepatocytes and HSC
in acute and chronic liver
injuries. a (top row) Quiescent
hepatocytes show persistent
phosphorylation of Smad3 at
its C-terminus by ActRI.
After acute liver injury, the
TGF-β-mediated pSmad3C
signaling terminates hepatocytic
proliferation induced by the
TNF-α-mediated mitogenic
pSmad3L pathway. b (top row)
After acute liver injury, TGF-β
and TNF-α synergistically
enhance the collagen synthesis
of activated HSC via the
pSmad2L/C and pSmad3L/C
pathways. During the
progression of chronic liver
diseases, pre-neoplastic
hepatocytes (a bottom row)
persistently affected by TGF-β
together with TNF-α start to
exhibit the same oncogenic
(mitogenic) pSmad3L and
fibrogenic pSmad2L/C
signaling as MFB (b, bottom
row), thereby accelerating
liver fibrosis and increasing
the risk of hepatocellular
carcinoma
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1998, 2000a). This raises the problem as to how hepatocytes
manage to proliferate in response to the mitogenic pro-
inflammatory cytokine signal, despite elevated TGF-β and
activin concentrations. During liver regeneration, hepatocytes
acquire temporary resistance to TGF-β and activin A,
allowing them to proliferate (Date et al. 1998, 2000a,
2000b). The phosphorylation pattern of Smad3 in regenerative
hepatocytes after acute liver injury suggests an important
participation of phospho-Smad3 in hepatocytic growth
regulation. In actively growing hepatocytes, the intracellular
phosphorylation at Smad3L is increased (Matsuzaki et al.
2007;M u r a t ae ta l .2009;N a g a t ae ta l .2009;F i g .5a,
top middle). Translocated to the nucleus, inflammatory
cytokine-induced pSmad3L stimulates c-Myc transcription
(Matsuzaki et al. 2007; Nagata et al. 2009; Kawamata et al.
2011), which increases the proliferation of hepatocytes and
opposes the cytostatic action of the pSmad3C/p21
WAF1
pathway (Fig. 3b). Accordingly, pSmad3C/p21
WAF1 is
undetectable in regenerative hepatocytic nuclei; an escape
from TGF-β/activin-induced cytostasis is crucial in a subset
of progenitor cells devoted to ensuring epithelial renewal.
Thus, a shift from cytostatic pSmad3C to mitogenic pSmad3L
signaling can permit liver regeneration in response to
mitogenic pro-inflammatory cytokines, even though TGF-β
and activin concentrations are elevated after acute liver injury.
Liver regeneration is tightly controlled by a delicate
balance between hepatocytic growth and inhibition. Anti-
mitotic effects of TGF-β contribute to the termination of
hepatocyte proliferation observed following the wave of
DNA synthesis in the regenerating liver. A return of TGF-β
sensitivity at later stages may limit hepatocyte proliferation
and terminate liver regeneration (Date et al. 1998, 2000b).
After a TNF-α and pSmad3L decrease, hepatocytic
proliferation ceases, as decreases in pSmad3L can increase
sensitivity to phosphorylation at Smad3C by TβRI
(Figs. 3c, 5a, top right). TGF-β-dependent pSmad3C
appears to limit the proliferative response of regenerating
hepatocytes through the inhibition of the G1-to-S phase
cell-cycle transition.
Phospho-Smad signaling in HSC after acute liver
injury: involvement of the pSmad2L/C and pSmad3L/C
pathways
Afteracuteliverdamage,HSCacquireanactivatedphenotype
associated with gradual loss in retinoid content, which
enhances cell proliferation/invasion and synthesis of large
amounts of ECM components, particularly various types of
collagens. How does cytostatic TGF-β signaling in HSC
take on collagen-producing features within inflammatory
microenvironments during acute liver injury? To answer this
question, we have focused onthe Smad pathway, investigating
the localization of pSmad2L/C and pSmad3L/C in chemically
injured rat livers. These phosphoisoforms are involved in
collagen synthesis andtransmit a proliferative invasiveTGF-β
signal in mesenchymal cells (Fig. 4a). Nuclear localization of
pSmad2L/C and pSmad3L/C is seen in the activated HSC
(Yoshida et al. 2005;F i g .5b, top right). In particular, strong
Smad2/3 phosphorylation at the COOH-tail and threonine
residues in the linker regions (Fig. 2b) is observed in the
activated HSC (Yoshida et al. 2005; unpublished data).
Because TGF-β, pro-inflammatory cytokines, and PDGF
activate CDK4 via the JNK pathway in HSC (Reeves et al.
2000: Yoshida et al. 2005; Zhang et al. 2005; Kluwe et al.
2010;F i g .4a), pro-inflammatory cytokines and PDGF can
convert a cytostatic TGF-β signal into a collagen-producing
character in activated HSC under the influence of inflamma-
tory microenvironments. Collectively, pSmad2L/C and
pSmad3L/C signaling might mobilize HSC from the space
of Disse to sites of damage, where the activated HSC
contribute to tissue repair by producing large amounts of
collagens (Fig. 5b, top right).
Spatial and temporal dynamics of R-Smad
phosphoisoforms: differences between epithelial
and mesenchymal cells
In contrast to the presence of the COOH-tail phosphorylation
of R-Smad in almost all cell types and tissues, the timing,
duration, extent, and functional implications of linker
phosphorylation depend on the cell type and context.
Therefore, the influence of linker phosphorylation on
COOH-tail phosphorylation has been an unsettled subject
with various data suggesting that mitogen-mediated linker
phosphorylation either inhibits (Kretzschmar et al. 1999;
Engel et al. 1999; Wicks et al. 2000; Grimm and Gurdon
2002;M o r ie ta l .2004;H oe ta l .2005; Javelaud and Mauviel
2005;S e k i m o t oe ta l .2007; Arany et al. 2008; Hamajima et
al. 2009;M i l l e te ta l .2009; Lin et al. 2010;H o n ge ta l .2010)
or enhances (Brown et al. 1997; de Caestecker et al. 1998;
Oft et al. 2002; Funaba et al. 2002; Hayashida et al. 2003;
Furukawa et al. 2003;M a t s u u r ae ta l .2004; Yoshida et al.
2005; Kamaraju and Roberts 2005;Y a n ge ta l .2008; Wang
et al. 2009; Matsuzaki et al. 2009; Alarcón et al. 2009;
He et al. 2010;M a t s u u r ae ta l .2010; Sasseville et al. 2010;
Rachakonda et al. 2010; Jiang et al. 2010; Burch et al. 2010;
van der Velden et al. 2011)e v e n t sd o w n s t r e a mo fT βRI.
Possible explanations exist for these different outcomes.
An involvement of the various mitogen-associated
kinases might explain outcomes differing among various
cell types and contexts. Normal epithelial cells show rapid
phosphorylation at the linker regions in response to various
mitogens, and the responsible kinases appear to act before
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localized in the cytoplasm and directly phosphorylates the
linker regions, creating pSmad2L and pSmad3L (Mori et al.
2004; Sekimoto et al. 2007). In contrast, mesenchymal cells
show phosphorylation of R-Smad at their linker regions,
and their kinases act after nuclear translocation of pSmad2C
and pSmad3C in response to TGF-β (Wang et al. 2009;
Matsuzaki et al. 2009; Alarcón et al. 2009; Matsuura et al.
2010; Figs. 4a, 5b, top). Localized in the nucleus, CDKs
directly phosphorylate the linker regions of pSmad2C
and pSmad3C, producing pSmad2L/C and pSmad3L/C
(Matsuura et al. 2004, 2010; Matsuzaki et al. 2009; Alarcón
et al. 2009).
TGF-β and mitogens exert mutually antagonistic effects
on cell-cycle control and apoptosis in normal epithelial cells
(Moses et al. 1990;F i g s .3, 5a, top). The mitogen
drastically alters Smad3 signaling via the JNK pathway,
increasing basal nuclear pSmad3L activity while shutting
down TGF-β-dependent pSmad3C that otherwise would be
available to act in the nuclei of normal epithelial cells.
Because migogenic pSmad3L signaling is followed by
cytostatic pSmad3C signaling during normal epithelial
regeneration, pSmad2L/C and pSmad3L/C rarely exist in
normal epithelial cells either in vitro or in vivo (Figs. 3, 5a,
top). In contrast, TGF-β and mitogenic signaling synergis-
tically promote the growth and invasion of mesenchymal
cells (Matsuzaki et al. 2009;M a t s u u r ae ta l .2010).
Blocking of either linker or COOH-tail phosphorylation
of Smad2 abrogates the synergistic responses of fibroblasts
to TGF-β and mitogens (Matsuzaki et al. 2009), indicating
an involvement of pSmad2L/C in this synergistic
mesenchymal cell response (Figs. 4, 5b).
Phospho-Smad signaling shared between pre-neoplastic
hepatocytes and MFB during chronic liver injury:
involvement of carcinogenic (mitogenic) pSmad3L
and fibrogenic pSmad2L/C pathways
Current evidence suggests that the regulation of ECM
accumulation in acute and chronic liver diseases involves
various mechanisms, even though HSC are the principal
effector in both cases (Friedman 2010). As a result of chronic
liver damage, HSC undergo progressive activation to become
MFB-like cells. During transdifferentiation in culture,
pSmad3C-mediated signal decreases, whereas the pSmad3L
pathway predominates (Furukawa et al. 2003;F i g .4b,l e f t ) .
The observations fully support the finding of pSmad3L rather
than pSmad3C in the nuclei of α-smooth muscle actin
(SMA)-immunoreactive MFB in the portal tracts of
chronically HCV-infected liver specimens (Matsuzaki et al.
2007;F i g .5b, bottom middle). The presence of α-SMA
is associated with the transdifferentiation of HSC into
scar-forming MFB, an event that is considered pivotal in
the fibrogenic response (Pinzani and Macias-Barragan 2010).
Similarly to MFB, hepatocytes in HCV-infected livers
exhibit phosphorylation at Smad3L, particularly those
adjacent to inflamed portal tracts (Matsuzaki et al. 2007;
Fig. 5a, bottom middle). Thus, hepatocytes are regulated by
the same pSmad3L pathway as are MFB. The extent of the
phosphorylation at Smad3L is less in hepatocytes distant
from portal tracts, in sharp contrast to pSmad3C, which is
predominantly located in hepatocytic nuclei distant from
portal tracts (Matsuzaki et al. 2007). TGF-β and pro-
inflammatory cytokines are released from infiltrating
Kupffer cells in portal tracts to activate JNK (Yoshida et
al. 2005; Kluwe et al. 2010). These findings, together with
in vitro data (Fig. 3b), suggest that pro-inflammatory
cytokine-dependent JNK can convert Smad3 to pSmad3L
in both affected hepatocytes and MFB in chronic hepatitis
(Fig. 5a, b, lower middle).
During the carcinogenic process, chronic inflammation
drives carcinogenesis via a shift from the tumor-suppressive
pSmad3C to the oncogenic pSmad3L pathway (Matsuzaki et
al. 2007;N a g a t ae ta l .2009). Many tumor-enhancing effects
of pro-inflammatory cytokines on hepatocytes are exerted at
the level of tumor promotion (Grivennikov et al. 2010).
TNF-α promotes HCC occurrence in mice lacking the P-
glycoprotein Mdr2 (Pikarsky et al. 2004). Cholestatic
inflammation in these mice is followed by HCC. HCC
incidence can be enhanced by another member of the TNF
family, lymphotoxin β (Haybaeck et al. 2009). Tumor-
promoting cytokines produced by Kupffer cells activate
several transcription factors such as nuclear factor kappa B,
signal transducer and activator of transcription 3, and
activator protein 1 in pre-malignant hepatocytes (He and
Karin 2011). The activated transcription factors stimulate the
transcription of their target genes involved in hepatocytic
proliferation and survival, which represents a major tumor-
promoting mechanism. Similar to these transcription factors,
the presence of hepatocytic Smad3 in human chronic liver
diseases is rarely the result of direct mutations (Roberts et al.
2006). Instead, pSmad3L depends on mitogenic pro-
inflammatory cytokine signals produced by neighboring
Kupffer cells.
Pre-neoplastic hepatocytes and HCC show a reduction of
anti-mitogenic responses to TGF-β (Matsuzaki et al. 2000a,
2000b). Escaping the cytostatic action of pSmad3C is a
critical step for progression to full malignancy in cancers,
which must overcome multiple fail-safe genetic controls
(Wakefield and Roberts 2002; Pardali and Moustakas
2007; Massagué 2008). The TGF-β/pSmad3C pathway is
required for the maintenance of genomic stability, induction
of replicative senescence, and suppression of telomerase
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Selection for genetic instability occurs in clones of aberrant
cells able to produce tumors, since genetic instability
greatly accelerates the accumulation of further genetic and
epigenetic changes required for tumor progression.
Evidence that fibrosis is reversible has intensified interest
inthe regulation ofmatrixdegradation and fibrosis resolution.
Data from transgenic mice that overexpress PAI-1 and from
PAI-1-knockout mice support a role in vivo for PAI-1
in experimental fibrotic diseases (Eitzman et al. 1996).
Moreover, the introduction of a PAI-1 small interfering
RNA attenuates the deposition of ECM and hydroxyproline
content in experimental hepatic fibrosis (Hu et al. 2009).
Plasma TGF-β,T N F - α, and PAI-1 concentrations are
usually elevated in patients with chronic liver diseases
(Shirai et al. 1994;T i l ge ta l .2006; Sugano et al. 2003).
How does TGF-β signaling in hepatocytes and MFB acquire
pro-fibrogenic properties under persistent inflammatory
microenvironments during chronic liver injury? Since
pSmad2L/C transmits a fibrogenic signal by stimulating
PAI-1 transcription (Fig. 4b, right), we have investigated the
pSmad2L/C pathway in human chronic liver disease. The
results indicate the nuclear localization of pSmad2L/C in
PAI-1-immunoreactive MFB and hepatocytes in chronic
hepatitis specimens (Tahashi et al. 2002;F u r u k a w ae ta l .
2003; Matsuzaki et al. 2007; unpublished data). Various
reports demonstrate transcriptional induction of the PAI-1
gene by TGF-β and TNF-α (Nagamine 2008). Thus, TGF-β
and TNF-α can mediate pSmad2L/C signaling, which
induces PAI-1 expression and promotes ECM deposition in
hepatocytes and MFB, accelerating liver fibrosis (Fig. 5a, b,
lower right).
We have recently proposed a colorectal cancer model of
tumorgrowthandinvasionthatinvolvesprogressiveincreases
in pSmad2L/C and pSmad3L, with the inhibition of tumor-
suppressive pSmad3C signaling (Yamagata et al. 2005;
Matsuzaki et al. 2009; Kawamata et al. 2011). Invasive
pSmad2L/C together with oncogenic pSmad3L can mediate
pro-tumorigenic TGF-β signaling, which allows carcinomas
to acquire the invasive and proliferative properties needed
for progression (another related review, manuscript in
preparation). Malignant phenotypes can be induced by tumor
microenvironments rather than by genetic changes within
carcinomas (Weinberg 2007). Because benign colorectal
tumors lack inflammatory microenvironments, these tumors
do not show pro-inflammatory cytokine/TGF-β dependence;
rather, they develop into colorectal cancers independently of
any fibrotic process. In contrast, hepatocytes in chronic
hepatitis are strongly influenced by stromally produced
pro-inflammatory cytokines, PDGF, and TGF-β signals
(Gotzmann et al. 2006), and pre-neoplastic hepatocytes
affected by inflammatory microenvironments can show
fibrogenic pSmad2L/C and oncogenic pSmad3L signaling
(Fig. 5a, lower right). Consequently, human chronic hepatitis
usually progresses to HCC in a process closely related to
hepatic fibrosis.
Our model supports previous reports showing that
hepatocytes promote fibrogenesis via a TGF-β/Smad signal.
Dooley et al. (2008)h a v er e p o r t e dt h a to v e r e x p r e s s i o no ft h e
inhibitory Smad7 in hepatocytes attenuates TGF-β-mediated
fibrogenesis by blocking the Smad signal. Because the large
latent TGF-β complex, consisting of TGF-β,t h eN - t e r m i n a l
part of its precursor, and the latent TGF-β binding protein,
exists in not only HSC but also hepatocytes, it can transmit
the pro-fibrogenic signal (Roth-Eichhorn et al. 1998),
although the intracellular functions of the TGF-β complex
remain unknown. The TGF-β down-stream mediator,
connective tissue growth factor (CTGF), also involves
hepatic fibro-carcinogenesis (Weng et al. 2007). CTGF
expression increases in fibrotic livers and various tumor
tissues (Gressner 2009). More importantly, in vivo knock-
down of CTGF by small interfering RNA leads to
the substantial attenuation of experimental liver fibrosis.
Differential regulation of CTGF expression in hepatocytes
and HSC by the Smad2 signal might contribute to hepatic
fibro-carcinogenesis (Gressner et al. 2007). Interestingly,
metylxanthine caffeine inhibits the synthesis of CTGF in
hepatocytes and HSC, primarily by inducing the degradation
of Smad2 (Gressner 2009).
JNK/pSmad3L pathway is an important target
for therapy against emergence of HCC
Clinical analyses of pSmad3L and pSmad3C in human tumor
formation have provided substantial mechanistic insights. For
example, specimens from patients with chronic hepatitis C
who develop HCC show abundant Smad3L but limited
Smad3Cphosphorylationinhepatocyticnuclei,whereasother
patients with abundant hepatocytic pSmad3C but limited
pSmad3L do not develop HCC (Matsuzaki et al. 2007).
During HCV-related hepatocarcinogenesis, JNK-activated
chronic inflammation confers a selective advantage on pre-
neoplastic hepatocytes by shifting Smad3 signaling from the
tumor-suppressive pSmad3C to the oncogenic pSmad3L
pathway, leading to HCC (Fig. 6). The same relationships
are observed in human HBV-related hepatocarcinogenesis
(Murata et al. 2009). These clinical observations support a
role for pSmad3C as a tumor-suppressor and for pSmad3L as
a promoter during human carcinogenesis.
The inhibition of TNF-α receptor and JNK by using
genetic, pharmacologic, or antibody-mediated approaches
abolishes human tumors in a tumor-cell-autonomous
fashion, indicating that the TNF-α/JNK cascade promotes
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important regulator of Smad3 signaling and increases the
basal amount of hepatocytic pSmad3L available for cell
growth while inactivating the TGF-β-dependent cytostatic
actions of pSmad3C (Fig. 3), pharmacologic interference with
JNK/pSmad3L signaling might interrupt carcinogenesis. A
key therapeutic aim in chronic liver disorders is the
restoration of the lost tumor-suppressive function observed
in normal hepatocytes, at the expense of effects promoting
hepatic carcinogenesis (Felsher 2004). To accomplish this
difficult aim, Nagata et al. (2009) administered a JNK
inhibitor SP600125 into rats and were able to suppress
chemical hepatocarcinogenesis by shifting hepatocytic Smad3
signaling from the oncogenic pSmad3L pathway to the
tumor-suppressive pSmad3C pathway (Fig. 6). This study
provides proof-of-principle that the JNK/pSmad3L pathway
is an important target for therapy devised to reduce the
emergence of HCC in the context of chronic liver injury.
We should also consider whether the long-term use of
drugs inhibiting C-terminal phosphorylation of R-Smad
might itself cause cancer development (Bellam and
Pasche 2010).
Concluding remarks and perspectives
This review summarizes current information available
concerning Smad phosphoisoform-mediated signals and
shows the similarities and differences between epithelial and
mesenchymal cells in acute and chronic liver injuries. After
acute liver injury, TGF-β-mediated pSmad3C signaling
terminates the hepatocytic proliferation induced by the pro-
inflammatory cytokine-mediated mitogenic pSmad3L path-
way; TGF-β and pro-inflammatory cytokines synergistically
enhance collagen synthesis by activated HSC via the
pSmad2L/C and pSmad3L/C pathways. An important issue
is the requirement of particular Smads in the regulation of
gene-specific transcriptional responses. In this regard, data
from Smad3
−/− mice indicate that Smad3 regulates epithelial
cell growth, whereas Smad2 principally mediates the ECM
responses in mesenchymal cells (Ashcroft et al. 1999).
Moreover, R-Smad phosphoisoform-mediated signals merit
further consideration with regard to different R-Smad
signaling between epithelial and mesenchymal cells.
TGF-β signaling shared in common between affected
hepatocytes and MFB in chronic liver disorders has received
less attention. During the progression of chronic liver diseases,
pre-neoplastic hepatocytes persistently affected by TGF-β
together with pro-inflammatory cytokines come to exhibit the
same oncogenic (mitogenic) pSmad3L and fibrogenic
pSmad2L/C signaling as do MFB, thereby accelerating liver
fibrosis, while increasing the risk of HCC. Our model can be
recognized as a crucial molecular mechanism by whichthevast
majority of HCC cases arise in the context of established
fibrosis or cirrhosis (Thorgeirsson and Grisham 2002).
Thus, the Smad phosphoisoform functions as an important
orchestrator of the human chronic inflammation-fibrosis-HCC
axis (Elsharkawy and Mann 2007).
Most of the information that we possess has been obtained
by studying cells in culture and by examining samples from
animals and human patients. Ultimately, we need to examine
whether domain-specific phosphorylation of R-Smad is
essential for hepatic fibro-carcinogenesis. Conditional knock-
out mice selectively altered with respect to domain-specific
phosphorylation will provide definitive information about R-
Smad phosphoisoformpathways and genetargetsthatinvolve
hepatic fibro-carcinogenesis (research currently underway).
This information is also critical for planning the use of
Fig. 6 Reversible shifting
of hepatocytic Smad3-dependent
signaling between tumor-
suppression and carcinogenesis.
During the carcinogenic process
in human chronic liver diseases,
chronic inflammation drives
carcinogenesis via a shift from
the pSmad3C to the pSmad3L
pathway. Linker phosphorylation
of Smad3 indirectly prevents
Smad3C phosphorylation,
pSmad3C-mediated transcription,
and the cytostatic effect of TGF-β/
activin upon hepatocytes.
Inhibition of JNK activity
abolishes pSmad3L-mediated
oncogenic signaling, while
restoring the lost tumor-
suppressive pSmad3C signaling
observed in normal hepatocytes
238 Cell Tissue Res (2012) 347:225–243domain-specific phosphorylation inhibitors to treat other
fibrotic diseases.
Chronic hepatitis B and C can be cured if patients are treated
with antiviral therapy that ceases chronic inflammation by
eradicating hepatic HBV and HCV populations. Multiple
prospective and retrospective analyses have suggested that the
successful therapy of chronic hepatitis can improve liver
fibrosis accompanied by a reduction of HCC incidence
(Yoshida et al. 1999; Shiratori et al. 2000). Prevention appears
to be most effective when therapy is given before the
development of cirrhosis. In chronic viral hepatitis, HCC
occurrence clearly depends on the presence of chronic
inflammation. Many patients with cirrhosis have evolved
beyond a dependence on inflammation, because their
hepatocytes have acquired genetic and epigenetic carcinogenic
properties. We are presently carrying out several trials to
determine whether antiviral therapy can decrease liver fibrosis
and lower HCC incidence. The trials will have a bearing upon
important questions with regard to the relative participation
in fibro-carcinogenesis of inflammation-dependent and
oncogene-dependent Smad phosphoisoform signaling in
HBV- and HCV-related chronic liver disorders. In the trials,
pathologic analyses with domain-specific phospho-Smad Abs,
together with clinical data, will evaluate the benefits of
antiviral therapy that decreases the stimulation of the
inflammation-dependent Smad phosphoisoform pathway.
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